Tag: Dialysis

Erythropoiesis-stimulating agents (ESAs) like epoetin are crucial for managing anemia associated with chronic conditions, with millions of doses administered annually. For many patients, a critical question arises: What is the best time to inject epoetin to maximize its effectiveness and minimize side effects? The answer is more complex than a simple "morning or evening" and depends heavily on individual patient factors.

Approved by the FDA in 1989, PROCRIT (epoetin alfa) is indeed given at dialysis to combat anemia, a common complication of chronic kidney disease. This medication helps stimulate the production of red blood cells, which can significantly reduce the need for blood transfusions.

While symptomatic hypermagnesemia is uncommon in individuals with healthy kidneys, it is a rare but serious electrolyte disorder that can occur in patients with renal failure or due to excessive magnesium intake. Understanding what reverses high magnesium is crucial for healthcare professionals and for preventing severe complications, which can range from respiratory depression to cardiac arrest.

While clinically significant hypermagnesemia is uncommon, it occurs in approximately 10% to 15% of hospitalized patients with kidney failure [1.7.1]. Knowing how do you get rid of magnesium toxicity is critical as severe cases can be fatal [1.2.1].

Despite being a common local anesthetic and antiarrhythmic, the clearance of lidocaine by hemodialysis is negligible. This is a crucial point for managing patients with kidney failure, where understanding *is lidocaine cleared by dialysis?* informs critical dosing decisions.

Hypermagnesemia, or high magnesium, is an uncommon electrolyte disorder, but its prevalence among hospitalized patients in the U.S. has been found to be as high as 9.3% [1.11.1]. Medically addressing 'How can I flush magnesium out of my system?' is critical as severe cases can be fatal [1.2.1].

While intravenous sodium thiosulfate is a therapeutic option for calciphylaxis, a rare and severe disorder, its use is associated with several potential adverse effects. This medication, often used off-label for this condition, has a known safety profile that patients and clinicians must understand and manage carefully.

Approximately 81% of people with chronic kidney disease (CKD) in Stage 4 and Stage 5 develop secondary hyperparathyroidism (SHPT). Zemplar (paricalcitol) is a medication specifically designed to prevent and treat this complication by acting as an active form of vitamin D.

Cinacalcet (brand name Sensipar) is a calcimimetic agent that works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands to extracellular calcium. It is an important medication for controlling high parathyroid hormone (PTH) levels, and the generic version offers a potentially more affordable option for many patients.

Over one-third of adult patients undergoing dialysis for chronic kidney disease (CKD) suffer from hyperphosphatemia, a dangerous condition caused by an excess of phosphate in the blood. It is in these critical cases that **sevelamer carbonate is used for** to help control and lower dangerously high phosphate levels.